Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy. (February 2016)

• Record Type: Journal Article
• Authors: Biton, Yitschak; Kutyifa, Valentina; Cygankiewicz, Iwona; Goldenberg, Ilan; Klein, Helmut; McNitt, Scott; Polonsky, Bronislava; Ruwald, Anne Christine; Ruwald, Martin H.; Moss, Arthur J.; Zareba, Wojciech
• Is Part Of: Circulation. Volume 9:Number 2(2016)
• Publication Date: 2016-02
• Subjects: bundle-branch block -- heart failure -- implanted cardioverter–defibrillator -- morbidity/mortality -- resynchronization; Heart failure -- Periodicals; 616.129005
• DOI: 10.1161/CIRCHEARTFAILURE.115.002667
• Languages: English
• ISSNs: 1941-3289

Abstract

Abstract : Background—: There are conflicting data regarding the efficacy of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and without left bundle branch block. Methods and Results—: We evaluated the long-term clinical outcomes of 537 non–left bundle branch block patients with mild HF enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study by QRS duration or morphology further stratified by PR interval. At 7 years of follow-up, the cumulative probability of HF hospitalization or death was 45% versus 56% among patients randomized to implantable cardioverter–defibrillator and CRT with defibrillator (CRT-D), respectively ( P =0.209). Multivariable-adjusted subgroup analysis by QRS duration showed that patients from the lower quartile QRS duration group (⩽134 ms) experienced 2.4-fold ( P =0.015) increased risk for HF hospitalization or death with CRT-D versus implantable cardioverter–defibrillator only therapy, whereas the effect of CRT-D in patients from the upper quartiles group (QRS>134 ms) was neutral (hazard ratio [HR] =0.97, P =0.86; P value for interaction =0.024). In a second analysis incorporating PR interval, patients with prolonged QRS (>134 ms) and prolonged PR (>230 ms) were protected with CRT-D (HR=0.31, P =0.003), whereas the association was neutral with prolonged QRS (>134 ms) and shorter PR (⩽230 ms;, HR=1.19, P =0.386; P value for interaction =0.002). The effect was neutral, regardless of morphology, right bundle branch block (HR=1.01, P =0.975), and intraventricular conduction delay (HR=1.31, P =0.172). Conclusions—: Overall, patients with mild HF but without left bundle branch block morphology did not derive clinical benefit with CRT-D during long-term follow-up. Relatively shorter QRS was associated with a significantly increased risk with CRT-D relative to implantable cardioverter–defibrillator -only. Clinical Trial Registration—: URL:http://www.clinicaltrials.gov . Unique identifiers: NCT00180271, NCT01294449, and NCT02060110. Abstract : Supplemental Digital Content is available in the text.